686 results on '"Poluzzi, Elisabetta"'
Search Results
2. Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
3. Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals
4. Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis
5. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
6. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
7. Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
8. Ethical Review of In Silico Methodologies
9. Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
10. Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
11. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
12. Authors’ Reply to Cappello et al. Comment on: “Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System”
13. Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants
14. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
15. ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance
16. Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective.
17. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.
18. Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
19. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
20. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance
21. Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems
22. The prevalence of polypharmacy in older Europeans: A multi‐national database study of general practitioner prescribing.
23. The evolving role of disproportionality analysis in pharmacovigilance.
24. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
25. Leveraging digital medication adherence technologies to enhance sustainability of European health systems: ENABLE’s key recommendations
26. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
27. The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
28. Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
29. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
30. Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study
31. A collection of Predicted No-Effect Concentrations of human pharmaceuticals and their metabolites
32. Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
33. Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis
34. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system
35. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
36. The Prevalence of Polypharmacy In Older Europeans: A Multi-country Database Study of General Practitioner Prescribing
37. Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System
38. Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward.
39. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety
40. Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
41. Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
42. Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
43. Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary
44. Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice
45. Appropriateness of Proton Pump Inhibitor prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy
46. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas
47. The environmental impact of pharmaceuticals in Italy : Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies
48. The environmental impact of pharmaceuticals in Italy: integrating healthcare and eco‐toxicological data to assess and potentially mitigate their diffusion to water supplies
49. Estimating the environmental impact of antibiotics through drug utilisation and eco-toxicological data: The italian context
50. Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.